| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
|
Lysyl oxidase inhbitor 1 is a novel and potent inhibitor of lysyl oxidase, whose upregulation by tumor cells may promote metastasis of the existing tumor, causing it to become malignant and cancerous. Thus it has the potential to be used in the treatment of cancer.
| ln Vitro |
The substance 33, LOX-IN-3 dihydrochloride monohydrate, has an IC50 value of less than 10 μM for bovine LOX and less than 1 μM for human LOXL2 activity [1]. Long-term inhibition of LOXL1 and LOXL2 is demonstrated by LOX-IN-3 dihydrochloride monohydrate [1]. In terms of SSAO/VAP-1 and MAO-B activity, LOX-IN-3 dihydrochloride monohydrate is less active [1].
|
|---|---|
| ln Vivo |
Compound 33, LOX-IN-3 dihydrochloride monohydrate (30 mg/kg; oral; once) inhibits the activity of rat lysyl oxidase [1]. A mouse model of unilateral ureteral obstruction (UUO) showing reduced renal fibrosis responds well to LOX-IN-3 dihydrochloride monohydrate (10 mg/kg; oral; once daily for 14 days) (1). Mice treated orally with LOX-IN-3 dihydrochloride monohydrate (15 mg/kg; once daily for 21 days) have less pulmonary fibrosis [1].
|
| Animal Protocol |
Animal/Disease Models: Male Wistar rat[1]
Doses: 30 mg/kg Route of Administration: Orally, single dose Experimental Results:Complete elimination of lysyl oxidase activity. Plasma concentrations of the test compound were well below the IC50 after 8 hrs (hrs (hours)), and the recovery half-life was between 2-3 days (ear) and 24 hrs (hrs (hours)) (aorta). Animal/Disease Models: Mouse unilateral ureteral obstruction (UUO) model of acute renal fibrosis [1] Doses: 10 mg/kg Route of Administration: po (oral gavage), one time/day for 14 days Experimental Results: Increased kidney weight and thickness, fiber The area is diminished. Animal/Disease Models: C57Bl/6 mice, bleomycin-induced pulmonary fibrosis model. Doses: 15 mg/kg. Route of Administration: po (oral gavage), one time/day for 21 days. Experimental Results: Dramatically diminished Ashcroft score and lung weight. |
| References | |
| Additional Infomation |
Pan-LOX Inhibitor PXS-5505 is an orally available, small-molecule, irreversible inhibitor of all lysyl oxidases (LOX) family members, with potential antifibrotic activity. Upon oral administration, pan-LOX inhibitor PXS-5505 targets, binds to and inhibits the activity of all enzymes in the LOX family. This prevents the post-translational oxidative deamination of lysine residues on target proteins, including collagen and elastin, and reduces the formation of deaminated lysine (allysine), the formation of inter- and intramolecular cross-linkages and may prevent remodeling of the extracellular matrix (ECM), thereby reducing fibrotic tissue formation in certain chronic fibrotic diseases. LOX is often upregulated in fibrotic tissue and plays a key role in fibrosis.
|
| Molecular Formula |
C13H13FN2O2S
|
|---|---|
| Molecular Weight |
280.3179
|
| Exact Mass |
280.068
|
| CAS # |
2409963-83-1
|
| Related CAS # |
LOX-IN-3 dihydrochloride;2409964-23-2;LOX-IN-3 dihydrochloride monohydrate;2414974-55-1
|
| PubChem CID |
146317833
|
| Appearance |
White to off-white solid powder
|
| LogP |
0.4
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
19
|
| Complexity |
430
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
S(C([H])([H])/C(=C(\[H])/C([H])([H])N([H])[H])/F)(C1=C([H])C([H])=C([H])C2C([H])=C([H])C([H])=NC1=2)(=O)=O
|
| InChi Key |
DHXXLGDTPFPYRH-WDZFZDKYSA-N
|
| InChi Code |
InChI=1S/C13H13FN2O2S/c14-11(6-7-15)9-19(17,18)12-5-1-3-10-4-2-8-16-13(10)12/h1-6,8H,7,9,15H2/b11-6-
|
| Chemical Name |
(Z)-3-fluoro-4-quinolin-8-ylsulfonylbut-2-en-1-amine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~125 mg/mL (~445.92 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (7.42 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (7.42 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (7.42 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.5674 mL | 17.8368 mL | 35.6735 mL | |
| 5 mM | 0.7135 mL | 3.5674 mL | 7.1347 mL | |
| 10 mM | 0.3567 mL | 1.7837 mL | 3.5674 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
